A0030 The difference of anti-hypertensive drugs between KOREA and JAPAN

Abstract

Objectives: Anti-hypertensive drugs are used for hypertensive patients around the world. Methods: We examined the anti-hypertensive drugs between KOREA and JAPAN. Results: The usual dose of Amlodipine (Ca antagonist) is 5 mg in both countries. But the dose of Irbesartan (Angiotensin II receptor antagonist; ARB) is different. Korean irbesartan has 150 mg and 300 mg tablets, and about 30% Korean patients are taking 300 mg. The maximam recommended dose is 300 mg in Korea, is higher than 200 mg in Japan. The Ca antagonist/ARB combination product is equivalent. The Ca antagonist/statin combination product is approved in both countries, but the dose of statin is different. Rosuvastatin has 5 mg, 10 mg and 20 mg tablets, and Atorvastatin has 10 mg, 20 mg and 40 mg tablets in Korea. In contrast, Rosuvastatin has 2.5 mg and 5 mg tablets, and Atorvastatin has 5 mg and 10 mg tablets in Japan. The maximam recommended dose of statin is higher in Korea than one in Japan. The dose of ezetimibe (intestinal cholesterol transporter inhibitor) is not different 10 mg once daily in both countries. Conclusion: Compared to anti-hypertensive and anti-hyperlipidemic drugs, ARB and statin are regulated. The recommended dose of drugs depends on the effectiveness and safety in process of each examination approval.